ALZN
Alzamend Neuro, Inc.
Price Chart
Latest Quote
$1.68
+0.08 (+5.00%)
Current Price
| Previous Close | $1.60 |
| Open | $1.61 |
| Day High | $1.68 |
| Day Low | $1.61 |
| Volume | 20,711 |
Stock Information
| Shares Outstanding | 4.83M |
| Cash Equivalents | $711K |
| Net Income | $-8.77M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.11M |
| EPS (TTM) | $-2.63 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.96M |
| Income | $-8.77M |
| Book/sh | $0.17 |
| Cash/sh | $0.15 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.53 |
| Current Ratio | 1.31 |
Returns & Margins
| ROA | -163.99% |
| ROE | -373.18% |
Ownership
| Insider Ownership | 2.68% |
| Institutional Ownership | 56.76% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.93 |
| P/B | 9.77 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $26.00 |
Technical Indicators
| SMA20 | $1.53 |
| SMA50 | $1.36 |
| SMA200 | $1.61 |
| RSI | 65.22 |
| ATR | 0.1053 |
| Shares Float | 4.78M |
| Short Float | 3.70% |
| Short Ratio | 3.60 |
| Volatility | 0.19 |
| Rel Volume | 0.22 |
Performance History
| Week | +5.00% |
| Month | +25.37% |
| Quarter | +47.37% |
| 6 Months | -10.64% |
| YTD | -11.58% |
| Year | -31.15% |
| 3 Years | -99.54% |
| 5 Years | -99.96% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-01 | $1.68 | 20,711 |
| 2026-08-31 | $1.60 | 37,700 |
| 2026-08-28 | $1.66 | 242,100 |
| 2026-08-27 | $1.66 | 39,700 |
| 2026-08-26 | $1.67 | 125,300 |
| 2026-08-25 | $1.60 | 122,000 |
| 2026-08-24 | $1.55 | 133,800 |
| 2026-08-21 | $1.56 | 242,700 |
| 2026-08-20 | $1.63 | 486,200 |
| 2026-08-19 | $1.52 | 95,100 |
| 2026-08-18 | $1.52 | 37,500 |
| 2026-08-17 | $1.58 | 118,600 |
| 2026-08-14 | $1.55 | 87,500 |
| 2026-08-13 | $1.46 | 25,200 |
| 2026-08-12 | $1.44 | 19,700 |
| 2026-08-11 | $1.47 | 16,400 |
| 2026-08-10 | $1.46 | 27,700 |
| 2026-08-07 | $1.37 | 18,100 |
| 2026-08-06 | $1.38 | 59,400 |
| 2026-08-05 | $1.43 | 43,400 |
| 2026-08-04 | $1.45 | 149,500 |
| 2026-08-03 | $1.34 | 28,500 |
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
đ° Latest News
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-01-26T14:40:01Z
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
Zacks âĸ 2025-11-20T12:50:00Z
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
Benzinga âĸ 2025-11-19T12:30:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $6,619 | $18,029 | $10,101 | $7,701 |
| Total Expenses | $8,766,841 | $4,496,824 | $9,937,645 | $14,870,466 |
| Net Non Operating Interest Income Expense | $-5,541 | $-18,029 | $-10,101 | $-7,701 |
| Interest Expense Non Operating | $6,619 | $18,029 | $10,101 | $7,701 |
| Operating Expense | $8,766,841 | $4,496,824 | $9,937,645 | $14,870,466 |
| Selling And Marketing Expense | $425,000 | $347,295 | $247,334 | $742,601 |
| General And Administrative Expense | $4,712,056 | $2,734,601 | $3,235,204 | $6,682,008 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,772,382 | $-4,514,853 | $-9,947,746 | $-14,878,167 |
| Net Interest Income | $-5,541 | $-18,029 | $-10,101 | $-7,701 |
| Interest Income | $1,078 | $0 | - | - |
| Normalized Income | $-8,772,382 | $-4,514,853 | $-9,947,746 | $-14,878,167 |
| Net Income From Continuing And Discontinued Operation | $-8,772,382 | $-4,514,853 | $-9,947,746 | $-14,878,167 |
| Total Operating Income As Reported | $-8,766,841 | $-4,496,824 | $-9,937,645 | $-14,870,466 |
| Net Income Common Stockholders | $-8,772,382 | $-5,105,084 | $-9,947,746 | $-14,878,167 |
| Net Income | $-8,772,382 | $-4,514,853 | $-9,947,746 | $-14,878,167 |
| Net Income Including Noncontrolling Interests | $-8,772,382 | $-4,514,853 | $-9,947,746 | $-14,878,167 |
| Net Income Continuous Operations | $-8,772,382 | $-4,514,853 | $-9,947,746 | $-14,878,167 |
| Pretax Income | $-8,772,382 | $-4,514,853 | $-9,947,746 | $-14,878,167 |
| Interest Income Non Operating | $1,078 | $0 | - | - |
| Operating Income | $-8,766,841 | $-4,496,824 | $-9,937,645 | $-14,870,466 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.63 | $-11.32 | $-132.33 | $-228.90 |
| Basic EPS | $-2.63 | $-11.32 | $-132.33 | $-228.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,655,023 | $-4,446,084 | $-9,886,905 | $-14,847,400 |
| Reconciled Depreciation | $110,740 | $50,740 | $50,740 | $23,066 |
| EBITDA (Bullshit earnings) | $-8,655,023 | $-4,446,084 | $-9,886,905 | $-14,847,400 |
| EBIT | $-8,765,763 | $-4,496,824 | $-9,937,645 | $-14,870,466 |
| Diluted Average Shares | $3,337,143 | $450,799 | $75,174 | $65,012 |
| Basic Average Shares | $3,337,143 | $450,799 | $75,174 | $65,012 |
| Diluted NI Availto Com Stockholders | $-8,772,382 | $-5,105,084 | $-9,947,746 | $-14,878,167 |
| Research And Development | $3,629,785 | $1,414,928 | $6,455,107 | $7,445,857 |
| Selling General And Administration | $5,137,056 | $3,081,896 | $3,482,538 | $7,424,609 |
| Other Gand A | $2,645,535 | $964,624 | $1,117,360 | $1,276,507 |
| Insurance And Claims | $236,279 | $259,382 | $381,737 | $587,427 |
| Salaries And Wages | $1,830,242 | $1,510,595 | $1,736,107 | $4,818,074 |
| Preferred Stock Dividends | - | $590,231 | - | - |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-08-28
Balance Sheet (Annual)
| Metric | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $733,211 | $3,968,222 | $-2,594,185 | $3,045,503 |
| Total Assets | $2,079,363 | $4,602,983 | $631,588 | $5,915,625 |
| Total Non Current Assets | $314,866 | $425,606 | $176,346 | $79,843 |
| Current Assets | $1,764,497 | $4,177,377 | $455,242 | $5,835,782 |
| Prepaid Assets | $1,053,808 | $228,719 | $79,194 | $694,923 |
| Cash Cash Equivalents And Short Term Investments | $710,689 | $3,948,658 | $376,048 | $5,140,859 |
| Cash And Cash Equivalents | $710,689 | $3,948,658 | $376,048 | $5,140,859 |
| Cash Financial | $710,689 | $3,948,658 | $376,048 | $5,140,859 |
| Receivables | - | - | - | - |
| Current Deferred Assets | - | - | - | - |
| Other Receivables | - | - | - | - |
| Accrued Interest Receivable | - | - | - | - |
| Notes Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | $300,714 | - |
| Current Debt And Capital Lease Obligation | - | - | $300,714 | - |
| Current Debt | - | - | $300,714 | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,346,152 | $634,761 | $3,225,773 | $2,870,122 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $1,346,152 | $634,761 | $3,225,773 | $2,870,122 |
| Payables And Accrued Expenses | $1,346,152 | $634,761 | $2,925,059 | $2,870,122 |
| Payables | $1,346,152 | $634,761 | $2,925,059 | $2,870,122 |
| Accounts Payable | $1,346,152 | $634,761 | $2,925,059 | $2,870,122 |
| Current Notes Payable | - | $0 | $300,714 | $0 |
| Equity | ||||
| Common Stock Equity | $733,211 | $3,968,222 | $-2,594,185 | $3,045,503 |
| Total Equity Gross Minority Interest | $733,211 | $3,968,222 | $-2,594,185 | $3,045,503 |
| Stockholders Equity | $733,211 | $3,968,222 | $-2,594,185 | $3,045,503 |
| Retained Earnings | $-67,307,643 | $-58,535,261 | $-54,020,408 | $-44,072,662 |
| Other Equity Interest | - | - | - | $-14,883,295 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $3,804,741 | $778,732 | $76,444 | $71,807 |
| Share Issued | $3,804,741 | $778,732 | $76,444 | $71,807 |
| Tangible Book Value | $733,211 | $3,968,222 | $-2,594,185 | $3,045,503 |
| Invested Capital | $733,211 | $3,968,222 | $-2,293,471 | $3,045,503 |
| Working Capital | $418,345 | $3,542,616 | $-2,770,531 | $2,965,660 |
| Total Capitalization | $733,211 | $3,968,222 | $-2,594,185 | $3,045,503 |
| Additional Paid In Capital | $68,040,429 | $62,503,405 | $51,426,215 | $62,001,395 |
| Capital Stock | $425 | $78 | $8 | $65 |
| Common Stock | $425 | $78 | $8 | $65 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Net PPE | $314,866 | $425,606 | $176,346 | $79,843 |
| Treasury Shares Number | - | - | $0 | - |
| Dueto Related Parties Current | - | - | - | $0 |
Fetched: 2026-08-28
Cash Flow Statement (Annual)
| Metric | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,067,813 | $-6,868,186 | $-8,417,236 | $-8,923,152 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,067,813 | $-6,568,186 | $-8,269,993 | $-8,923,152 |
| Cash Flow From Continuing Operating Activities | $-8,067,813 | $-6,568,186 | $-8,269,993 | $-8,923,152 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-300,000 | $-147,243 | $0 |
| Cash Flow From Continuing Investing Activities | $0 | $-300,000 | $-147,243 | $0 |
| Capital Expenditure | - | $-300,000 | $-147,243 | - |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $4,829,844 | $10,440,196 | $3,352,425 | $0 |
| Financing Cash Flow | $4,829,844 | $10,440,796 | $3,652,425 | $200 |
| Cash Flow From Continuing Financing Activities | $4,829,844 | $10,440,796 | $3,652,425 | $200 |
| Net Preferred Stock Issuance | $4,035,000 | $7,736,144 | $2,100,000 | $0 |
| Preferred Stock Issuance | $4,035,000 | $7,736,144 | $2,100,000 | $0 |
| Net Common Stock Issuance | $794,844 | $2,704,052 | $1,252,425 | $0 |
| Common Stock Issuance | $794,844 | $2,704,052 | $1,252,425 | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| End Cash Position | $710,689 | $3,948,658 | $376,048 | $5,140,859 |
| Beginning Cash Position | $3,948,658 | $376,048 | $5,140,859 | $14,063,811 |
| Changes In Cash | $-3,237,969 | $3,572,610 | $-4,764,811 | $-8,922,952 |
| Proceeds From Stock Option Exercised | $0 | $600 | $0 | $200 |
| Net PPE Purchase And Sale | $0 | $-300,000 | $-147,243 | $0 |
| Purchase Of PPE | $0 | $-300,000 | $-147,243 | $0 |
| Change In Working Capital | $-113,698 | $-2,438,467 | $670,666 | $2,349,324 |
| Change In Payables And Accrued Expense | $711,391 | $-2,288,942 | $54,937 | $1,707,272 |
| Change In Prepaid Assets | $-825,089 | $-149,525 | $615,729 | $642,052 |
| Stock Based Compensation | $707,527 | $325,108 | $955,633 | $3,582,625 |
| Depreciation Amortization Depletion | $110,740 | $50,740 | $50,740 | $23,066 |
| Depreciation And Amortization | $110,740 | $50,740 | $50,740 | $23,066 |
| Depreciation | $110,740 | $50,740 | $50,740 | $23,066 |
| Net Income From Continuing Operations | $-8,772,382 | $-4,514,853 | $-9,947,746 | $-14,878,167 |
| Issuance Of Debt | - | $0 | $300,000 | $0 |
| Net Issuance Payments Of Debt | - | $0 | $300,000 | $0 |
| Net Short Term Debt Issuance | - | $0 | $300,000 | $0 |
| Short Term Debt Issuance | - | $0 | $300,000 | $0 |
| Other Non Cash Items | - | $9,286 | $714 | - |
| Repayment Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-08-28